Axios Pro Rata: Biotech… | Axios Pro Rata Summary

1. Key Themes

GLP-1 / Obesity Biotech Is the Hottest IPO Sector in the Market

Kailera Therapeutics' $625M IPO is the largest biotech IPO ever, surpassing Moderna's 2018 record. The deal priced above range (39.1M shares at $16 vs. 33.3M shares at $14–$16), signaling strong institutional demand. The obesity drug space is so strategically valuable that Big Pharma is actively hunting for acquisition targets post-IPO.

"Almost every Big Pharma company without an obesity program wants one, so don't be surprised if someone comes knocking on Kailera's door." "That's what happened to the last obesity issuer to go public — Metsera, which raised $289 million via IPO last January and then got acquired by Pfizer for $10 billion after a bidding war."

AI-Native Fund Structures Are Emerging as a New Venture Category

Jonathan Tower's departure from Prosperity7 to build an "AI-native" firm signals a structural shift in how new venture shops are being designed — smaller, flatter, and purpose-built for the AI era, rather than retrofitting legacy operating models.

"Tower plans to launch a new firm that he describes as 'AI-native.' Expect that to mean smaller and flatter than legacy shops." "We got things from 0 to 60, building everything from scratch because it was a brand with no mindshare or footprint in the U.S. Now I want to get off the bus and go build again."

The "Stranded Startup" Problem Is Large Enough to Attract Dedicated Capital

A new fund category is forming around startups that fell out of the hypergrowth narrative after Series A/B but aren't broken businesses — they're just mispriced. Alex Shtarkman's Antithesis Ventures is raising a $20M pilot to address this gap explicitly.

"The idea is to target the growing number of startups that get 'stranded' — often after a Series A or B round — because they're no longer growing at least 100% year-over-year, but were priced or otherwise structured as if they would."

Consumer & Experiential Investing Is Being Institutionalized Around a "Free Time" Macro Thesis

Sideline Group's $155M debut fund bets that structural increases in leisure time — driven first by remote work, then by AI — will create durable demand for in-person experiences across sports, media, and entertainment.

"The basic idea is to capitalize on a structural increase in free time — enabled now by remote work and in the future by AI — and the digitally-driven desire for in-person experiences."

2. Contrarian Perspectives

A Record Biotech IPO at a Lower Valuation Multiple Than Its Predecessor Is a Warning Sign

Despite breaking the all-time dollar record for a biotech IPO, Kailera's valuation is significantly below Moderna's 2018 benchmark on a relative basis. This suggests the market is paying for pipeline optionality but applying real discipline on pricing — the record is nominal, not qualitative.

"This is the largest biotech IPO ever, topping Moderna's $604 million raise in 2018." "Yes, but: Moderna scored a much higher valuation, as Kailera will list with around a $1.89 billion market cap."

Stranded Startups Are an Underserved Asset Class, Not a Graveyard

The consensus view treats post-Series A stagnation as a death spiral. Shtarkman's thesis flips this: these companies are structurally sound but narratively broken, creating an exploitable valuation gap for patient, specialized capital.

"The idea is to target the growing number of startups that get 'stranded' — often after a Series A or B round — because they're no longer growing at least 100% year-over-year, but were priced or otherwise structured as if they would."

Chinese Pharma IP Is Quietly Powering U.S. Biotech's Biggest Deals

Kailera's entire drug portfolio is licensed from China's Jiangsu Hengrui Pharmaceuticals, which retains a 13.6% pre-IPO stake. In an era of U.S.-China tension, one of the most celebrated U.S. biotech milestones is built on Chinese IP — a dynamic largely underreported in the coverage of this deal.

"China's Jiangsu Hengrui Pharmaceuticals, which licensed out a portfolio of GLP-1 drugs to Kailera, holds a 13.6% pre-IPO position."

3. Companies Identified

Kailera Therapeutics

Description: Waltham, MA-based Phase 3 GLP-1 drug developer for obesity; Nasdaq: KLRA
Why mentioned: Executed the largest biotech IPO in history at $625M, backed by Bain Capital (45.9% stake), RTW, CPPIB, Atlas Venture, and others
Quote: "This is the largest biotech IPO ever, topping Moderna's $604 million raise in 2018."

Metsera

Description: Obesity drug developer that went public in January 2025
Why mentioned: Serves as the precedent case for GLP-1 IPO-to-acquisition pipeline; acquired by Pfizer for $10B after a bidding war
Quote: "Metsera...raised $289 million via IPO last January and then got acquired by Pfizer for $10 billion after a bidding war."

Prosperity7

Description: Aramco Ventures affiliate managing ~$3B in venture assets, including AI infrastructure bets
Why mentioned: Portfolio company case study; Jonathan Tower built its U.S. operations from zero
Quote: "Prosperity7 currently manages around $3 billion, including investments in Groq, Cohere, and Together AI."

Sideline Group

Description: Debut PE fund ($155M) focused on consumer, sports, media, and entertainment
Why mentioned: New firm built around the "structural free time" macro thesis; already invested in Miami Open, Madrid Open owner MARI and others
Quote: "The basic idea is to capitalize on a structural increase in free time — enabled now by remote work and in the future by AI."

Antithesis Ventures

Description: Early-stage special situations VC fund; raising $20M pilot
Why mentioned: Novel fund category targeting "stranded" post-Series A/B startups
Quote: "The idea is to target the growing number of startups that get 'stranded.'"

Plata

Description: Mexican digital bank; raised $405M Series C at $5B valuation
Why mentioned: One of the largest LatAm fintech rounds in recent memory; led by Bicycle Capital with QIA and BTG Pactual participating
Quote: Raised "a $405m Series C round at a $5b valuation."

Factory

Description: SF-based enterprise AI coding startup
Why mentioned: Raised $150M at $1.5B valuation; backed by Khosla, Blackstone, Insight, and Sequoia — notable crossover institutional support
Quote: "Factory...raised $150m at a $1.5b valuation. Khosla Ventures led, joined by Blackstone, Insight Partners, and Sequoia Capital."

Ulysses

Description: SF-based maker of autonomous submarines
Why mentioned: Raised $38M Series A led by a16z with Booz Allen and Harpoon Ventures; signals continued defense-tech VC momentum
Quote: "Ulysses, an SF-based maker of autonomous submarines, raised $38m in Series A funding. A16z led, joined by Booz Allen Ventures and Harpoon Ventures."

Alamar Biosciences

Description: Fremont, CA-based protein biomarker detection platform; Nasdaq: ALMR
Why mentioned: Priced above range in IPO, raising $191M — another sign of healthy biotech public market appetite
Quote: "Alamar Biosciences...raised $191m in its IPO. It priced 11.3m shares at $17, versus plans to offer 9.4m at $15-$17."

Vox Media

Description: Digital media company owning New York Magazine, The Verge, and a podcast network
Why mentioned: Planning to sell major assets separately — a sign of ongoing media fragmentation and distress
Quote: "Vox Media is planning to sell several assets via separate sales, including its podcast network, New York magazine and The Verge."

MARI (Ari Emanuel's events group)

Description: Events company owning the Miami Open and Madrid Open tennis tournaments
Why mentioned: Early Sideline Group portfolio investment; validates the experiential/sports investment thesis
Quote: "Sideline already has made five investments, including Ari Emanuel's MARI, an events group that owns the Miami Open and Madrid Open."

4. People Identified

Jonathan Tower

Description: Outgoing head of U.S. ventures at Prosperity7 (Aramco Ventures affiliate)
Why mentioned: Building a new "AI-native" VC firm; led Prosperity7's U.S. buildout including investments in Groq, Cohere, and Together AI
Quote: "Now I want to get off the bus and go build again."

Greg Mazlin

Description: Former Tiger Global partner (short-selling side); founder of Sideline Group
Why mentioned: Raised $155M debut PE fund; previously invested own capital in the Miami Heat
Quote: "Mazlin was on Tiger's short-selling side, focusing on struggling legacy consumer companies."

Alex Shtarkman

Description: Former Revolution venture partner (7+ years); founder of Antithesis Ventures
Why mentioned: Launching novel "early-stage special situations" fund targeting stranded startups
Quote: "It's called Antithesis Ventures, and is raising $20 million for what is essentially a pilot fund."

Michael Murray

Description: Partner at Paul Hastings; former DOJ deputy assistant attorney general for antitrust (Trump's first term)
Why mentioned: Being considered to lead DOJ antitrust enforcement — highly relevant for M&A deal-making environment
Quote: "President Trump is considering naming Michael Murray as DOJ's next antitrust enforcement chief."

Ari Emanuel

Description: Entertainment mogul; founder/operator of MARI events group
Why mentioned: His events company (Miami Open, Madrid Open) is an early Sideline Group portfolio investment, lending credibility to the experiential investing thesis
Quote: "Sideline already has made five investments, including Ari Emanuel's MARI, an events group that owns the Miami Open and Madrid Open."

5. Operating Insights

Build Brand and Market Presence Deliberately Before Seeking an Exit

Tower's framing of his Prosperity7 tenure as a "0 to 60" buildout — establishing mindshare and footprint before moving on — is a template for institutional investors launching in new geographies. The sequencing matters: you can't exit a brand-building phase early without leaving value on the table.

"We got things from 0 to 60, building everything from scratch because it was a brand with no mindshare or footprint in the U.S."

The GLP-1 IPO-to-Acquisition Playbook Is Now a Repeatable Template

For biotech founders and investors in the obesity/metabolic space, the Metsera precedent is instructive: IPO at a modest valuation to establish a public price anchor, then attract Big Pharma acquirers who need an obesity program and face build-vs-buy pressure. The strategy deliberately uses the public markets as a price discovery and acquisition signaling mechanism.

"Almost every Big Pharma company without an obesity program wants one, so don't be surprised if someone comes knocking on Kailera's door. That's what happened to the last obesity issuer to go public — Metsera, which raised $289 million via IPO last January and then got acquired by Pfizer for $10 billion after a bidding war."

Institutionalizing a Personal Track Record Requires a Clear Thesis Upgrade

Mazlin's path from personal investing (Miami Heat minority stake) to a $155M institutional fund was enabled by a clearly articulated macro thesis — not just deal history. The "structural free time" framing gave LPs a forward-looking framework, not just a backward-looking track record.

"He then decided to institutionalize the effort, building a small team and marketing a fund to back companies at the intersection of consumers, sports, media and entertainment."

6. Overlooked Insights

Sovereign and Institutional Capital Is Quietly Concentrating in GLP-1 Bets

Kailera's cap table reads like a who's-who of global institutional capital: CPPIB (Canada's largest pension), QIA (Qatar's sovereign wealth fund), T. Rowe Price, Janus Henderson, and Royalty Pharma all hold pre-IPO stakes. This level of cross-border sovereign concentration in a single Phase 3 biotech is unusual and suggests GLP-1 has become a macro-level strategic asset, not just a venture bet.

"It had raised around $1 billion from firms like Bain Capital (45.9% pre-IPO stake), RTW Investments (12.1%), CPPIB (5.9%), Atlas Venture (5.5%), Adage Capital Management, Invus, Janus Henderson, Perseverance Capital, QIA, Royalty Pharma, Surveyor Capital, T. Rowe Price, and Sirona Capital."

Blackstone Is Quietly Expanding Into Early-Stage Venture

Blackstone co-led Factory's $150M Series B alongside Khosla and Sequoia, and separately led TextQL's $17M raise — two very different deal sizes in the AI space. For a firm known for large-scale buyouts and credit, its growing presence in early venture rounds is worth watching as a signal of either strategy evolution or market-wide capital rotation into AI.

"Factory...raised $150m at a $1.5b valuation. Khosla Ventures led, joined by Blackstone, Insight Partners, and Sequoia Capital." "TextQL, an SF-based AI data analyst, raised $17m led by Blackstone."